Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Approval summary for bortezomib for injection in the treatment of multiple myeloma.
Bross PF, Kane R, Farrell AT, Abraham S, Benson K, Brower ME, Bradley S, Gobburu JV, Goheer A, Lee SL, Leighton J, Liang CY, Lostritto RT, McGuinn WD, Morse DE, Rahman A, Rosario LA, Verbois SL, Williams G, Wang YC, Pazdur R. Bross PF, et al. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3954-64. doi: 10.1158/1078-0432.CCR-03-0781. Clin Cancer Res. 2004. PMID: 15217925 Clinical Trial. No abstract available.
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.
de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, Ouyang Y, Saber H, Lee K, Koti K, Rothmann M, Shapiro M, Borrego F, Clouse K, Chen XH, Brown J, Akinsanya L, Kane R, Kaminskas E, Farrell A, Pazdur R. de Claro RA, et al. Clin Cancer Res. 2012 Nov 1;18(21):5845-9. doi: 10.1158/1078-0432.CCR-12-1803. Epub 2012 Sep 7. Clin Cancer Res. 2012. PMID: 22962441
Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R. Kane RC, et al. Clin Cancer Res. 2006 Dec 15;12(24):7271-8. doi: 10.1158/1078-0432.CCR-06-1249. Clin Cancer Res. 2006. PMID: 17189398 Review.
Bortezomib for the treatment of mantle cell lymphoma.
Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R. Kane RC, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5291-4. doi: 10.1158/1078-0432.CCR-07-0871. Clin Cancer Res. 2007. PMID: 17875757 Clinical Trial.
Sorafenib for the treatment of unresectable hepatocellular carcinoma.
Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R. Kane RC, et al. Oncologist. 2009 Jan;14(1):95-100. doi: 10.1634/theoncologist.2008-0185. Epub 2009 Jan 14. Oncologist. 2009. PMID: 19144678 Free article. Review.
U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, Rothmann MD, Habtemariam B, Bullock J, Bray JD, Hawes J, Palmby TR, Jee J, Adams W, Mahayni H, Brown J, Dorantes A, Sridhara R, Farrell AT, Pazdur R. Herndon TM, et al. Among authors: kane rc. Clin Cancer Res. 2013 Sep 1;19(17):4559-63. doi: 10.1158/1078-0432.CCR-13-0755. Epub 2013 Jun 17. Clin Cancer Res. 2013. PMID: 23775332
U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.
Lee HZ, Miller BW, Kwitkowski VE, Ricci S, DelValle P, Saber H, Grillo J, Bullock J, Florian J, Mehrotra N, Ko CW, Nie L, Shapiro M, Tolnay M, Kane RC, Kaminskas E, Justice R, Farrell AT, Pazdur R. Lee HZ, et al. Among authors: kane rc. Clin Cancer Res. 2014 Aug 1;20(15):3902-7. doi: 10.1158/1078-0432.CCR-14-0516. Epub 2014 May 13. Clin Cancer Res. 2014. PMID: 24824310 Clinical Trial.
50 results